{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": {
    "pdf_name": "Liu_et_al.__2024_",
    "source_pdf": "data/clinical_files/Liu et al. (2024).pdf",
    "total_pages": 13,
    "total_blocks": 146,
    "total_characters": 36717
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 2,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.",
      "relevance_explanation": "This quote directly compares the antibody responses induced by the higher-dose recombinant vaccine (RIV4) to those induced by standard-dose egg-based vaccines (IIV4), showing that RIV4 produced higher neutralizing and total HA head binding antibodies to the A (H3 N2) virus, supporting the claim."
    },
    {
      "id": 2,
      "quote": "RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody response in both 18\u201344 years and 45\u201364 years, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).",
      "relevance_explanation": "This quote specifies that RIV4 is a higher-dose recombinant vaccine and provides evidence that it significantly increased both the quality and quantity of antibody responses to A (H3 N2) compared to standard-dose vaccines, directly supporting the claim."
    }
  ],
  "model_used": "gpt-4.1"
}